Dr. Trabulsi Defines Locally Advanced Prostate Cancer

Edouard J. Trabulsi, MD, FACS
Published: Monday, May 07, 2018



Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, defines locally advanced prostate cancer.

In defining a tumor as locally advanced, clinicians generally look at tumor parameters, such as clinical stage on a rectal exam, prostate-specific antigen (PSA), and Gleason score. These factors give an idea of a given patient’s risk category, Trabulsi says.

That information, plus imaging is used to determine whether a patient’s demonstrable disease outside of the prostate is high risk enough to lead to a strong prediction of locally advanced disease. This is done by inspecting results of imaging or a physical exam, Trabulsi explains.

For high-risk patients with locally advanced prostate cancer, researchers at Thomas Jefferson University Hospital are conducting a trial assessing cabazitaxel (Jevtana) in combination with hormone therapy and radiotherapy (NCT01420250).


Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, defines locally advanced prostate cancer.

In defining a tumor as locally advanced, clinicians generally look at tumor parameters, such as clinical stage on a rectal exam, prostate-specific antigen (PSA), and Gleason score. These factors give an idea of a given patient’s risk category, Trabulsi says.

That information, plus imaging is used to determine whether a patient’s demonstrable disease outside of the prostate is high risk enough to lead to a strong prediction of locally advanced disease. This is done by inspecting results of imaging or a physical exam, Trabulsi explains.

For high-risk patients with locally advanced prostate cancer, researchers at Thomas Jefferson University Hospital are conducting a trial assessing cabazitaxel (Jevtana) in combination with hormone therapy and radiotherapy (NCT01420250).



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x